Vertex Pharmaceuticals

Vertex Pharmaceuticals

Yahoo Finance • 2 days ago

Vertex to Participate in Upcoming September Investor Conferences

BOSTON, August 26, 2026--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced management participation in four upcoming investor conferences. Susie Lisa, Senior Vice President of Investor Relations and Manis... Full story

Yahoo Finance • 4 days ago

Inflation Is Rising Again. History Says These 2 Stocks Are Among the Smartest Places to Hide

Inflation has increased in 2026 compared to last year, largely due to soaring energy and oil prices, although it has cooled down somewhat over the past two months. Still, we don't know what tomorrow holds. Inflation may rise significantly... Full story

Yahoo Finance • 10 days ago

3 Cash-Producing Stocks on Our Watchlist

3 Cash-Producing Stocks on Our Watchlist Businesses with strong free cash flow tend to be more adaptable and resilient. Some of these companies shine bright by using their cash wisely to strengthen their market positions. Identifying the... Full story

Yahoo Finance • 14 days ago

Vertex Pharmaceuticals (VRTX) Could Be 8% Undervalued Following Raised 2026 Guidance

Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. Vertex Pharmaceuticals (VRTX) has drawn fresh attention after reporting second quarter 2026 results, raising full year... Full story

Yahoo Finance • 14 days ago

BofA biotech scorecard: Two buys and odd one out

Picture three students turning in exams on the same day, covering the same material. Two walk away with high marks. The third has been raising his grades all semester, yet still gets flagged for summer school. That is roughly the dynamic... Full story

Yahoo Finance • 15 days ago

Inside Latigo Biotherapeutics’ IPO: A Non-Opioid Pain Bet Goes Public

Quick Read LTGO priced its IPO at $18, opened at $21, and raised nearly $350 million from an oversubscribed offering. LTG-001 delivered 50% greater pain relief than hydrocodone in a 343-patient trial, positioning it for a first-ever opioi... Full story

Yahoo Finance • 17 days ago

One Company’s Clinical Miss Is Another’s Moat: Vertex Rallies as Sionna’s CF Bet Collapses

Cystic fibrosis investors came to learn a harsh lesson on August 10 about how concentrated a market can be: Sionna Therapeutics, Inc. (NASDAQ:SION) shares fell more than 90% following a key trial failure, while Vertex Pharmaceuticals (NASD... Full story

Yahoo Finance • 18 days ago

Why Sionna Therapeutics Stock Is Crashing 92% to a Record Low

The biotech says its cystic fibrosis drug candidate missed the mark in a Phase 2a trial, though the news could be a boon to shares of Vertex Pharmaceuticals. Continue Reading... Full story

Yahoo Finance • 18 days ago

Vertex Stock Jumps 5.9% as Rival Cystic Fibrosis Drug Fails

This article first appeared on GuruFocus. Vertex Pharmaceuticals (NASDAQ:VRTX), the biotech king of cystic fibrosis, jumped approximately 5.9% in Monday's regular session after a rival drug stumbled. Sionna Therapeutics said SION-719 miss... Full story

Yahoo Finance • 18 days ago

This Biotech’s Drug Could Treat Hot Flashes. The Stock Is Up 36% on Good News.

New data show a single dose of AbCellera’s menopause treatment, ABCL635, reduces how often patients with menopause experience hot flashes. Continue Reading... Full story

Yahoo Finance • 20 days ago

Earnings Scorecard: 95% of healthcare firms deliver EPS wins this week

Major healthcare heavyweights, including Pfizer (PFE [https://seekingalpha.com/symbol/PFE]), Merck (MRK [https://seekingalpha.com/symbol/MRK]), and Eli Lilly (LLY [https://seekingalpha.com/symbol/LLY]), reported their quarterly earnings th... Full story

Yahoo Finance • 23 days ago

AbCellera Biologics Inc (ABCL) (Q2 2026) Earnings Call Highlights: Strong Pipeline Progress and ...

This article first appeared on GuruFocus. Release Date: August 05, 2026 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points AbCellera Biologics Inc (NASDAQ:ABCL) complete... Full story

Yahoo Finance • 25 days ago

Vertex Pharmaceuticals Inc (VRTX) (Q2 2026) Earnings Call Highlights: Revenue Surges 12% to $3. ...

This article first appeared on GuruFocus. Total Revenue: $3.3 billion in Q2 2026, up 12% year-over-year. CF Revenue: Global CF revenue grew 11% year-over-year in Q2 2026. CASGEVY Revenue: $76 million in Q2 2026, up over 150% year-over-yea... Full story

Yahoo Finance • 25 days ago

Crinetics Pharmaceuticals GAAP EPS of -$1.14 beats by $0.07, revenue of $25.12M beats by $10.25M

* Crinetics Pharmaceuticals press release [https://seekingalpha.com/pr/20604770-crinetics-pharmaceuticals-reports-second-quarter-2026-financial-results-and-provides-business] (CRNX [https://seekingalpha.com/symbol/CRNX]): Q2 GAAP EPS of... Full story

Yahoo Finance • 25 days ago

After-Hours Earnings Report for August 3, 2026 : PLTR, VRTX, WMB, OKE, FANG, ON, SBAC, STRL, JAZZ, BWXT, GRAB, TKO

The following companies are expected to report earnings after hours on 08/03/2026. Visit our Earnings Calendar for a full list of expected earnings releases. Palantir Technologies Inc. (PLTR)is reporting for the quarter ending June 30,... Full story

Yahoo Finance • 27 days ago

XLV vs. IBBQ: Is Broad Healthcare Exposure or Biotech Growth the Better ETF Buy?

The State Street Health Care Select Sector SPDR ETF (NYSEMKT:XLV) provides broad exposure to the S&P 500 healthcare sector, whereas the Invesco Nasdaq Biotechnology ETF (NASDAQ:IBBQ) offers a targeted focus on biotechnology and pharmaceuti... Full story

Yahoo Finance • 27 days ago

XLV vs PBE: Is a Low-Cost Healthcare ETF the Better Buy Than a Focused Biotech Specialist?

The State Street Health Care Select Sector SPDR ETF (NYSEMKT:XLV) offers broad exposure to the S&P 500 healthcare sector at a low cost, whereas the Invesco Biotechnology & Genome ETF (NYSEMKT:PBE) targets a concentrated niche of biotechnol... Full story

Yahoo Finance • 28 days ago

3 things to look out for on Monday

[Wall Street sign, New York City, USA] mbbirdy/E+ via Getty Images Wall Street ended higher on Friday, lifted by Amazon (AMZN [https://seekingalpha.com/symbol/AMZN])—whose shares climbed on strong quarterly results—as well as semiconducto... Full story

Yahoo Finance • 29 days ago

Morgan Stanley Nearly Doubled Its Price Target for CRISPR Therapeutics. Is the Gene-Editing Stock a No-Brainer Buy?

Key Points CRISPR Therapeutics recently won a key label expansion. The company has important data readouts on the horizon. The stock is somewhat risky given the possibility of clinical failures. 10 stocks we like better than CRISPR Therap... Full story

Yahoo Finance • 29 days ago

VHT vs. PBE: Which Health Care ETF Is the Better Buy?

The Invesco Biotechnology & Genome ETF (NYSEMKT:PBE) offers a focused, high-momentum approach to the biotechnology sector, while the Vanguard Health Care ETF (NYSEMKT:VHT) provides broad, low-cost exposure across the entire healthcare land... Full story